These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 15794284)

  • 21. Cost-effectiveness of pharmacy and group behavioural support smoking cessation services in Glasgow.
    Boyd KA; Briggs AH
    Addiction; 2009 Feb; 104(2):317-25. PubMed ID: 19149829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The ATTEMPT cohort: a multi-national longitudinal study of predictors, patterns and consequences of smoking cessation; introduction and evaluation of internet recruitment and data collection methods.
    West R; Gilsenan A; Coste F; Zhou X; Brouard R; Nonnemaker J; Curry SJ; Sullivan SD
    Addiction; 2006 Sep; 101(9):1352-61. PubMed ID: 16911736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost effectiveness of community-based physical activity interventions.
    Roux L; Pratt M; Tengs TO; Yore MM; Yanagawa TL; Van Den Bos J; Rutt C; Brownson RC; Powell KE; Heath G; Kohl HW; Teutsch S; Cawley J; Lee IM; West L; Buchner DM
    Am J Prev Med; 2008 Dec; 35(6):578-88. PubMed ID: 19000846
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and validation of a microsimulation economic model to evaluate the disease burden associated with smoking and the cost-effectiveness of tobacco control interventions in Latin America.
    Pichon-Riviere A; Augustovski F; Bardach A; Colantonio L;
    Value Health; 2011; 14(5 Suppl 1):S51-9. PubMed ID: 21839900
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Costs of exacerbations of chronic obstructive pulmonary disease in primary and secondary care in 2007--results of multicenter Polish study].
    Jahnz-Rózyk K; Targowski T; From S
    Pol Merkur Lekarski; 2009 Mar; 26(153):208-14. PubMed ID: 19388534
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Panel on cost-effectiveness in health and medicine recommendations: identifying costs.
    Manning WG
    J Clin Psychiatry; 1999; 60 Suppl 3():54-6; discussion 57-8. PubMed ID: 10073379
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Socioeconomic burden of hip fractures in Germany].
    Weyler EJ; Gandjour A
    Gesundheitswesen; 2007 Nov; 69(11):601-6. PubMed ID: 18080931
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost of depression in Europe.
    Sobocki P; Jönsson B; Angst J; Rehnberg C
    J Ment Health Policy Econ; 2006 Jun; 9(2):87-98. PubMed ID: 17007486
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A national hypertension treatment program in Germany and its estimated impact on costs, life expectancy, and cost-effectiveness.
    Gandjour A; Stock S
    Health Policy; 2007 Oct; 83(2-3):257-67. PubMed ID: 17335933
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Costs of heart disease and risk behaviour: implications for expenditure on prevention.
    Kruse M; Davidsen M; Madsen M; Gyrd-Hansen D; Sørensen J
    Scand J Public Health; 2008 Nov; 36(8):850-6. PubMed ID: 19004902
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Spending decisions for tobacco-related disease treatment and tobacco control: an example and a solution.
    Thomson G; Wilson N
    N Z Med J; 2005 Feb; 118(1210):U1337. PubMed ID: 15776107
    [No Abstract]   [Full Text] [Related]  

  • 33. Cost-effectiveness analysis: what is it and how will it influence neurology.
    Holloway RG
    Ann Neurol; 1996 Jun; 39(6):818-23. PubMed ID: 8651658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Unequal discounting of health care costs and effects causes confusion].
    van Ballegooijen M; de Kok IM; Habbema JD
    Ned Tijdschr Geneeskd; 2010; 154():A1970. PubMed ID: 20619050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Focus on smoking cessation or drugs--2].
    Lindberg M
    Ugeskr Laeger; 2004 Jan; 166(3):178-9; author reply 179. PubMed ID: 14870652
    [No Abstract]   [Full Text] [Related]  

  • 36. [Focus on smoking cessation or drugs?].
    Lindberg M
    Ugeskr Laeger; 2003 Dec; 165(50):4872; author reply 4872-3. PubMed ID: 14716911
    [No Abstract]   [Full Text] [Related]  

  • 37. Behavioral interventions and cost-effectiveness analysis.
    Wagner TH; Goldstein MK
    Prev Med; 2004 Dec; 39(6):1208-14. PubMed ID: 15539057
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The economic and human costs of smoking in Minnesota.
    Welch D; Daly K; Hilton J
    Minn Med; 1995 Apr; 78(4):19-22. PubMed ID: 7760782
    [No Abstract]   [Full Text] [Related]  

  • 39. The challenges of estimating the national costs of osteoarthritis: are we making progress?
    Maetzel A
    J Rheumatol; 2002 Sep; 29(9):1811-3. PubMed ID: 12233870
    [No Abstract]   [Full Text] [Related]  

  • 40. Do cost-effectiveness analyses cause you dyspepsia?
    Ganiats TG
    J Fam Pract; 1997 Jun; 44(6):541-2. PubMed ID: 9191625
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.